Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDER Says Keeping Avastin Breast Cancer Claim Would Undermine Accelerated Approval Process

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Center for Drug Evaluation and Research intends to argue at a June hearing that the accelerated approval system will operate as a lower standard if bevacizumab's breast cancer indication is maintained while Genentech conducts another confirmatory trial.

You may also be interested in...



Cancer Approval Standards, FDA Reputation At Stake With Avastin Hearing, NEJM Authors Say

In separate perspective pieces in the New England Journal of Medicine, Boston academics criticize the 2008 approval of bevacizumab's breast cancer claim based on progression-free survival and warn the agency's credibility will be undermined if the claim is not withdrawn.

Cancer Approval Standards, FDA Reputation At Stake With Avastin Hearing, NEJM Authors Say

In separate perspective pieces in the New England Journal of Medicine, Boston academics criticize the 2008 approval of bevacizumab's breast cancer claim based on progression-free survival and warn the agency's credibility will be undermined if the claim is not withdrawn.

Genentech Banking On Biomarker Data To Save Avastin In Breast Cancer

Genentech is counting on biomarker data gathered across the Avastin development program – in addition to a new assay developed by parent company Roche – to help it retain the VEGF inhibitor’s accelerated approval in metastatic breast cancer.

Related Content

Topics

UsernamePublicRestriction

Register

PS072240

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel